ArticleEndocrine pathology2005
Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas.
Article in Endocrine pathology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.Pituitary · 2018Pooled it
- Silent corticotroph adenomas.Pituitary · 2015Pooled it
- High-risk pituitary adenomas and strategies for predicting response to treatment.Hormones (Athens, Greece) · 2022Review
- Association of PTTG1 expression with invasiveness of non-functioning pituitary adenomas.Journal of pathology and translational medicine · 2022Article
- Review
- Circulating Galectin-3 Evaluation in Dogs With Cardiac and Non-cardiac Diseases.Frontiers in veterinary science · 2021Article
- Article
- Non-classical role of Galectin-3 in cancer progression: translocation to nucleus by carbohydrate-recognition independent manner.BMB reports · 2020Review
- Gene expression profiling in human corticotroph tumours reveals distinct, neuroendocrine profiles.Journal of neuroendocrinology · 2018Article
- Immunohistochemical Biomarkers in Thyroid Pathology.Endocrine pathology · 2018Review
- Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination.Frontiers in cellular neuroscience · 2018Review
- MicroRNAs in the human pituitary.Endocrine pathology · 2011Review
- MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas.Endocrine · 2010Article
- Review
- Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells.Neuroscience bulletin · 2008Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Galectin-3 (Gal-3), a beta galactoside-binding protein, has been implicated in a variety of biological functions including cell growth, differentiation, tumor cell adhesion, angiogenesis, tumor progression, and metastasis. We recently reported that Gal-3 was expressed in a subset of normal pituitary cells and tumors including PRL, ACTH, and in folliculo-stellate (FS) cells and tumors and that Gal-3 had an important regulatory role in pituitary cell proliferation. We further investigated the expression of Gal-3 protein in ACTH- and PRL-producing tumors and the expression of various galectin mRNAs by RT-PCR in pituitary adenomas and normal pituitary. Most silent ACTH subtypes 1 and 2 adenomas were negative or only focally positive for Gal-3 expression compared to functioning ACTH tumors from patients with Cushing's disease and Nelson's syndrome. In the normal pituitary, Gal-3 was expressed in less than 1% of the basophil-invading cells (ACTH cells present in the posterior pituitary) and in a subset of the anterior lobe ACTH-positive cells. RT-PCR analyses showed that many members of the galectin family including galectins 1, 2, 3, 4, 5, 6, 7, 8, and 9 were expressed in normal pituitary and in functioning ACTH- and PRL-producing tumors. These results indicate that Gal-3 is associated with functioning ACTH and PRL tumors and is expressed infrequently in silent ACTH adenomas, suggesting that Gal-3 protein and/or gene is altered in non-functioning ACTH tumors. The use of ACTH and Gal-3 immunostaining should help in the diagnosis of silent ACTH adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.